Anti -FGF-23 (Fibroblast Growth Factor 23, Tumor-derived Hypophosphatemia-inducing Factor)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 12; NC_000012.11 (4477393..4488894, complement). Location: 12p13.3

Monoclonal

IgG1,k

FG322-3

Mouse

Recognizes human FGF-23. Does not cross-react with mouse FGF-23.

Affinity Purified
Purified by Protein A affinity chromatography.

Supplied as a liquid in 0.2um-filtered PBS, pH 7.4. No preservative added.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-FGF23 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

FGF-23 is a regulator of phosphate homeostasis. It upregulates EGR1 expression in the presence of KLBy. Acts directly on the parathyroid to decrease PTH secretion. Regulates the vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF-23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) and of hyperphosphatemic familial tumoral calcinosis (HFTC).

Antibodies; Abs to Growth Factors, Cytokines

ELISA (EL/EIA), Western Blot (WB), Immunohistochemistry (IHC)

Suitable for use in ELISA, Immunohistochemistry, Western Blot

27,954 Da[Similar Products]

fibroblast growth factor 23

fibroblast growth factor 23; phosphatonin; tumor-derived hypophosphatemia inducing factor

Fibroblast growth factor 23

HYPF; FGF-23??[Similar Products]

FGF23_HUMAN

This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013]

Function: Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL

By similarity. Acts directly on the parathyroid to decrease PTH secretion

By similarity. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Ref.2 Ref.8 Ref.13 Ref.14 Ref.16

Subunit structure: Interacts with FGFR1, FGFR2, FGFR3 and FGFR4. Affinity between fibroblast growth factors (FGFs) and their receptors is increased by KL and heparan sulfate glycosaminoglycans that function as coreceptors

By similarity. Ref.14

Subcellular location: Secreted. Note: Secretion is dependent on O-glycosylation. Ref.15

Tissue specificity: Expressed in osteogenic cells particularly during phases of active bone remodeling. In ***** trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts). Ref.11

Post-translational modification: Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23. Ref.15

Involvement in disease: Hypophosphatemic rickets, autosomal dominant (ADHR) [MIM:193100]: A disease characterized by isolated renal phosphate wasting, hypophosphatemia, and inappropriately normal 1,25-dihydroxyvitamin D3 (calcitriol) levels. Patients frequently present with bone pain, rickets, and tooth abscesses.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.2 Ref.8 Ref.15Tumoral calcinosis, hyperphosphatemic, familial (HFTC) [MIM:211900]: A severe metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Some patients manifest recurrent, transient, painful swellings of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis and absence of skin involvement.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.19

Sequence similarities: Belongs to the heparin-binding growth factors family.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.